| (1S,4R)-CC-90005 |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| (E/Z)-Chk2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-AR-13503 |
|
|
|
|
|
|
|
|
|
|
|
98.20% |
| (rac)-AR-13503 |
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| (Rac)-Aurora A/PKC-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| (S)-Ro 32-0432 |
|
|
|
|
|
|
|
|
|
|
|
|
| (S)-Ro 32-0432 free base |
|
|
|
|
|
|
|
|
|
|
|
|
| 1,2-Didecanoyl-Sn-glycerol |
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| 1,2-Didecanoylglycerol |
|
|
|
|
|
|
|
|
|
|
|
|
| 1,2-Dimyristoyl-sn-glycerol |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| 1,2-Dipentadecanoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| 1,2-Dimyristoyl-rac-glycerol |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Iso-H7 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| 1-Oleoyl-2-acetyl-sn-glycerol |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| 1-Oleoyl-2-linoleoyl-sn-glycerol |
|
|
|
|
|
|
|
|
|
|
|
|
| 1-Stearoyl-2-Arachidonoyl-d8-sn-Glycerol |
|
|
|
|
|
|
|
|
|
|
|
|
| 1-Stearoyl-2-arachidonoyl-sn-glycerol |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| 12-Deoxyphorbol 13-isobutyrate |
|
|
|
|
|
|
|
|
|
|
|
|
| 12-Deoxyphorbol-13-isobutyrate-20-acetate |
|
|
|
|
|
|
|
|
|
|
|
|
| 18:0-22:6 DG |
|
|
|
|
|
|
|
|
|
|
|
99% |
| 3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine |
|
|
|
|
|
|
|
|
|
|
|
|
| Bisindolylmaleimide I hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| 3-Methyl-L-tyrosine |
|
|
|
|
|
|
|
|
|
|
|
|
| Desmethylglycitein |
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| 4α-TPA |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| 6-Deoxyisojacareubin |
|
|
|
|
|
|
|
|
|
|
|
|
| 7,4'-Dimethoxy-3-hydroxyflavone |
|
|
|
|
|
|
|
|
|
|
|
|
| 7-Hydroxystaurosporine |
|
|
|
|
|
|
|
|
|
|
|
97.8% |
| 7-Oxostaurosporine |
|
|
|
|
|
|
|
|
|
|
|
|
| [Ala107]MBP(104-118) |
|
|
|
|
|
|
|
|
|
|
|
|
| [Ala107]MBP(104-118) acetate |
|
|
|
|
|
|
|
|
|
|
|
|
| [Ala107]MBP(104-118) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| [Ala113]MBP(104-118) |
|
|
|
|
|
|
|
|
|
|
|
|
| [Ala113]MBP(104-118) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| [Ala9,10, Lys11,12] Glycogen Synthase (1-12) |
|
|
|
|
|
|
|
|
|
|
|
|
| [Glu27]-PKC (19-36) |
|
|
|
|
|
|
|
|
|
|
|
|
| [Ser25] Protein Kinase C (19-31) |
|
|
|
|
|
|
|
|
|
|
|
|
| A-3 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Ac-MBP (1-11) |
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-MBP (4-14) Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| AE 51310 |
|
|
|
|
|
|
|
|
|
|
|
|
| Afuresertib |
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| Afuresertib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| AJH-836 |
|
|
|
|
|
|
|
|
|
|
|
|
| Ala-MPSD |
|
|
|
|
|
|
|
|
|
|
|
|
| Anemonin |
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| aPKC-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Aprinocarsen sodium |
|
|
|
|
|
|
|
|
|
|
|
98.42% |
| Aprinocarsen sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
| AR-13503 |
|
|
|
|
|
|
|
|
|
|
|
98.21% |
| AS2521780 |
|
|
|
|
|
|
|
|
|
|
|
|
| Aurora A/PKC-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Aurothiomalate tetramer sodium |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Balanol |
|
|
|
|
|
|
|
|
|
|
|
|
| BHA536 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bisindolylmaleimide I |
|
|
|
|
|
|
|
|
|
|
|
98.15% |
| Bisindolylmaleimide II |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Bisindolylmaleimide III |
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| Bisindolylmaleimide IV |
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Bisindolylmaleimide VIII |
|
|
|
|
|
|
|
|
|
|
|
|
| Bisindolylmaleimide VIII acetate |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Bisindolylmaleimide X |
|
|
|
|
|
|
|
|
|
|
|
|
| Bisindolylmaleimide X hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.90% |
| Bisindolylmaleimide XI hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.91% |
| BJE6-106 |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Bryostatin 2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bryostatin 3 |
|
|
|
|
|
|
|
|
|
|
|
|
| C8 Dihydroceramide |
|
|
|
|
|
|
|
|
|
|
|
|
| Calphostin A |
|
|
|
|
|
|
|
|
|
|
|
|
| Calphostin C |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Cathepsin G |
|
|
|
|
|
|
|
|
|
|
|
|
| CC-90005 |
|
|
|
|
|
|
|
|
|
|
|
99.11% |
| CDK8-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| CGP-53353 |
|
|
|
|
|
|
|
|
|
|
|
98.87% |
| CGP60474 |
|
|
|
|
|
|
|
|
|
|
|
98.90% |
| Cholesterol sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
| Cholesterol sulfate-d7 sodium |
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Cholesteryl sulfate sodium |
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Chrysosplenol C |
|
|
|
|
|
|
|
|
|
|
|
|
| CIDD-0072424 |
|
|
|
|
|
|
|
|
|
|
|
|
| CMPD101 |
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| CMPD101 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| CP-46665 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| CREBtide |
|
|
|
|
|
|
|
|
|
|
|
98.33% |
| CREBtide TFA |
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| CRT0066854 |
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| CRT0066854 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| D-erythro-Sphingosine-13C2,d2 |
|
|
|
|
|
|
|
|
|
|
|
|
| D-erythro-Sphingosine-d7 |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| D-erythro-Sphingosine |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Daphnoretin |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Darovasertib |
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| DCP-LA |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| DCPLA-ME |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Delcasertib |
|
|
|
|
|
|
|
|
|
|
|
|
| Delcasertib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| Dioleyl phosphatidylserine |
|
|
|
|
|
|
|
|
|
|
|
|
| DL-erythro-Dihydrosphingosine |
|
|
|
|
|
|
|
|
|
|
|
98% |
| EGFR Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| Enzastaurin hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| ɛPKC(85–92),Myristoylated |
|
|
|
|
|
|
|
|
|
|
|
|
| Epsilon-V1-2 |
|
|
|
|
|
|
|
|
|
|
|
95.21% |
| Epsilon-V1-2, Cys-conjugated |
|
|
|
|
|
|
|
|
|
|
|
|
| Evo312 |
|
|
|
|
|
|
|
|
|
|
|
|
| Farnesylthiotriazole |
|
|
|
|
|
|
|
|
|
|
|
|
| Fasudil dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Fasudil mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
| FIM-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| FKKSFKL-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Gnidimacrin |
|
|
|
|
|
|
|
|
|
|
|
|
| Go 6983 |
|
|
|
|
|
|
|
|
|
|
|
|
| Go 6983 |
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Go 7874 |
|
|
|
|
|
|
|
|
|
|
|
|
| Go6976 |
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| GSK-3β inhibitor 13 |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| GSK-938890A |
|
|
|
|
|
|
|
|
|
|
|
|
| GSK-943949A |
|
|
|
|
|
|
|
|
|
|
|
|
| H-8 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| H-Arg-Gly-Tyr-Ala-Leu-Gly-OH |
|
|
|
|
|
|
|
|
|
|
|
|
| HA-100 |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| HA-100 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| HA-100 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| HBDDE |
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| Hispidin |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| HIV-1 inhibitor-65 |
|
|
|
|
|
|
|
|
|
|
|
|
| HIV-1 inhibitor-68 |
|
|
|
|
|
|
|
|
|
|
|
|
| HIV-1 protease-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
| HNS-32 |
|
|
|
|
|
|
|
|
|
|
|
|
| hRIO2 kinase ligand-1 |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Hu7691 |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Hu7691 free base |
|
|
|
|
|
|
|
|
|
|
|
|
| ICA-1S |
|
|
|
|
|
|
|
|
|
|
|
|
| ICP-103 |
|
|
|
|
|
|
|
|
|
|
|
|
| Ilmofosine |
|
|
|
|
|
|
|
|
|
|
|
|
| Ingenol 3-monobenzoate |
|
|
|
|
|
|
|
|
|
|
|
97.30% |
| Isojacareubin |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Isosalvianolic acid C |
|
|
|
|
|
|
|
|
|
|
|
|
| JH-131e-153 |
|
|
|
|
|
|
|
|
|
|
|
|
| Junicedric acid |
|
|
|
|
|
|
|
|
|
|
|
|
| JW480 |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| JW480 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
| K-252a |
|
|
|
|
|
|
|
|
|
|
|
99.02% |
| K-252b |
|
|
|
|
|
|
|
|
|
|
|
|
| K-252c |
|
|
|
|
|
|
|
|
|
|
|
|
| K-252d |
|
|
|
|
|
|
|
|
|
|
|
|
| Kaempferol 3-neohesperidoside |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Kiss2 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| Kiss2 peptide acetate |
|
|
|
|
|
|
|
|
|
|
|
|
| Kobophenol A |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| KRAKAKTTKKR |
|
|
|
|
|
|
|
|
|
|
|
|
| KRPpSQRHGSKY-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
| KS 619-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| KT5823 |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| L-α-Phosphatidylinositol-4,5-bisphosphate ammonium |
|
|
|
|
|
|
|
|
|
|
|
|
| LY 170198 |
|
|
|
|
|
|
|
|
|
|
|
|
| LY 379196 |
|
|
|
|
|
|
|
|
|
|
|
|
| Lyso-monosialoganglioside GM2 ammonium |
|
|
|
|
|
|
|
|
|
|
|
|
| Maackiain |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Malantide |
|
|
|
|
|
|
|
|
|
|
|
98.04% |
| Malantide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| MANS peptide |
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| MANS peptide TFA |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| MDL 27032 |
|
|
|
|
|
|
|
|
|
|
|
|
| Methyl arachidonate |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| MGF24 |
|
|
|
|
|
|
|
|
|
|
|
|
| Midostaurin-13C6 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mitoxantrone diacetate |
|
|
|
|
|
|
|
|
|
|
|
|
| Mitoxantrone hydrochloride liposome |
|
|
|
|
|
|
|
|
|
|
|
|
| Mitoxantrone-d8 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| ML191 |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| ML192 |
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| MPSD |
|
|
|
|
|
|
|
|
|
|
|
|
| MPSD control peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| MPSD TFA |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| MRS2768 tetrasodium salt |
|
|
|
|
|
|
|
|
|
|
|
98.7% |
| MS-553 |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| MT477 |
|
|
|
|
|
|
|
|
|
|
|
|
| Myelin Basic Protein |
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| Myelin basic protein (4-14) TFA |
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Myelin Basic Protein(87-99) TFA |
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Myelin basic protein, MBP (68-86) |
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Myr-Tat-PKCβII |
|
|
|
|
|
|
|
|
|
|
|
|
| N-Myristoyl-Lys-Arg-Thr-Leu-Arg |
|
|
|
|
|
|
|
|
|
|
|
|
| N-myristoyl-RKRTLRRL |
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| C8-Ceramide |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| NA 0345 |
|
|
|
|
|
|
|
|
|
|
|
|
| Neuropeptide DF2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Niazirin |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| NPC-15437 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.66% |
| NSC668394 |
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| O-Desmethyl Midostaurin |
|
|
|
|
|
|
|
|
|
|
|
97.08% |
| O-Desmethyl midostaurin-13C6 |
|
|
|
|
|
|
|
|
|
|
|
|
| OSU-2S |
|
|
|
|
|
|
|
|
|
|
|
|
| p32 Inhibitor M36 |
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| p38 MAPK-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| Pam2CSK4 |
|
|
|
|
|
|
|
|
|
|
|
|
| Pam2CSK4 TFA |
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| pep2-EVKI |
|
|
|
|
|
|
|
|
|
|
|
|
| Pep2m, myristoylated |
|
|
|
|
|
|
|
|
|
|
|
|
| Pep2m, myristoylated TFA |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| PF-03622905 |
|
|
|
|
|
|
|
|
|
|
|
|
| PF-04577806 |
|
|
|
|
|
|
|
|
|
|
|
|
| PF-4950834 |
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Phorbol 12,13-dibutyrate |
|
|
|
|
|
|
|
|
|
|
|
|
| Phorbol 12,13-dibutyrate |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Phosphate acceptor peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| PICK1 PDZ-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC 20-28,myristoylated |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC activator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC β pseudosubstrate |
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| PKC β pseudosubstrate TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC ζ pseudosubstrate |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| PKC-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC-iota inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| PKC-theta inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| PKC-theta inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| PKC-theta inhibitor 2 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC-ε translocation inhibitor peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| PKC/PKD-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
98.35% |
| PKCd (8-17) |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCiota-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCiota-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCiota-IN-2 formic |
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| PKCTheta-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCTheta-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| PKCα (C2-4) inhibitor peptide |
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| PKCα Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCβ inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| PKCβII Peptide Inhibitor I |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCδ Peptide Substrate |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCδ Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCε (85-92) |
|
|
|
|
|
|
|
|
|
|
|
98.50% |
| PKCε inhibitor peptide,myristoylated |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCε Inhibitor Scramble Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCε Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCζ Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCζ-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| PKCη pseudosubstrate inhibitor,myristoylated |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCθ pseudosubstrate peptide inhibitor,myristoylated |
|
|
|
|
|
|
|
|
|
|
|
|
| PKCθ pseudosubstrate peptide inhibitor,myristoylated TFA |
|
|
|
|
|
|
|
|
|
|
|
96.40% |
| PKCθ Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
|
| PKN1/2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Plantainoside D |
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| PLSRTLSVAAK |
|
|
|
|
|
|
|
|
|
|
|
|
| PRKCA Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkca Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkca Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| PRKCB Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkcb Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkcb Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| PRKCD Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkcd Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| PRKCE Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkce Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkce Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| PRKCG Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkcg Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkcg Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| PRKCH Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkch Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkch Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| PRKCI Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkci Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| PRKCQ Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkcq Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkcq Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| PRKCZ Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkd1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prkd1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Prostratin |
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Protein Kinase C (19-31) |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Protein Kinase C (19-31) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Kinase C (19-35) Peptide |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Protein Kinase C (19-36) |
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| Protein Kinase C (530-558) |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Kinase C (660-673) |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Kinase C (661-671) |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Kinase C Peptide Substrate |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein kinase C substrate |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein kinase C α peptide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Kinase C β Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Kinase C γ Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Kinase C,Rat |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein kinase inhibitor 7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein kinase inhibitor 9 |
|
|
|
|
|
|
|
|
|
|
|
|
| Protein kinase inhibitor H-7 |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Protein kinase inhibitor H-7 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| PS315 |
|
|
|
|
|
|
|
|
|
|
|
|
| PS432 |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Pseudo RACK1 |
|
|
|
|
|
|
|
|
|
|
|
|
| pTH-Related Protein (1-40) (human, mouse, rat) |
|
|
|
|
|
|
|
|
|
|
|
|
| Punicic acid |
|
|
|
|
|
|
|
|
|
|
|
98.5% |
| R 59-022 |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| R 59-022 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| R59949 |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| R8605 |
|
|
|
|
|
|
|
|
|
|
|
|
| Raxofelast |
|
|
|
|
|
|
|
|
|
|
|
|
| Reproxalap |
|
|
|
|
|
|
|
|
|
|
|
98.49% |
| Reproxalap (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
| RIM-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| RK-286D |
|
|
|
|
|
|
|
|
|
|
|
|
| Ro 31-8220 |
|
|
|
|
|
|
|
|
|
|
|
|
| Ro 31-8220 formic |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Ro 31-8220 mesylate |
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Ro 31-8830 |
|
|
|
|
|
|
|
|
|
|
|
|
| Rottlerin |
|
|
|
|
|
|
|
|
|
|
|
98.45% |
| Safingol |
|
|
|
|
|
|
|
|
|
|
|
|
| Safingol hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| SAMβA |
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| SAMβA TFA |
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| Sangivamycin |
|
|
|
|
|
|
|
|
|
|
|
97.68% |
| Sapintoxin A |
|
|
|
|
|
|
|
|
|
|
|
|
| Sapintoxin D |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| SB 220025 |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| SB 220025 (tri(hydrochloride)) |
|
|
|
|
|
|
|
|
|
|
|
|
| SB-218078 |
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| SB2960 |
|
|
|
|
|
|
|
|
|
|
|
|
| SBI-0087702 |
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| SC-10 |
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| SC-9 |
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| Senkyunolide B |
|
|
|
|
|
|
|
|
|
|
|
|
| Sotrastaurin |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Sotrastaurin acetate |
|
|
|
|
|
|
|
|
|
|
|
|
| Sphingosine (d14:1) |
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Spisulosine |
|
|
|
|
|
|
|
|
|
|
|
99.5% |
| Spisulosine-d3 |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Staurosporine |
|
|
|
|
|
|
|
|
|
|
|
|
| Staurosporine-Boc |
|
|
|
|
|
|
|
|
|
|
|
|
| Stearoyl-L-carnitine-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Stearoyl-L-carnitine-d9 chloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Stearoylcarnitine |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| TAS-301 |
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| TAT-P4-(DATC5)2 |
|
|
|
|
|
|
|
|
|
|
|
|
| TAT-P4-(DATC5)2 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| TAT-SAMβA |
|
|
|
|
|
|
|
|
|
|
|
|
| TCS 21311 |
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Teleocidin A1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Thyrotropin |
|
|
|
|
|
|
|
|
|
|
|
|
| Tigilanol tiglate |
|
|
|
|
|
|
|
|
|
|
|
96.35% |
| TPPB |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| TX-1123 |
|
|
|
|
|
|
|
|
|
|
|
|
| TX-1918 |
|
|
|
|
|
|
|
|
|
|
|
|
| UCN-02 |
|
|
|
|
|
|
|
|
|
|
|
95% |
| Vanicoside A |
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Variegatic acid |
|
|
|
|
|
|
|
|
|
|
|
|
| VTX-27 |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Xaliproden free base |
|
|
|
|
|
|
|
|
|
|
|
|
| Xaliproden hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| Z-Arg-SBzl |
|
|
|
|
|
|
|
|
|
|
|
96.58% |
| Z-Arg-SBzl TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| Endoxifen (Z-isomer) |
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Endoxifen Z-isomer hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| ZIP |
|
|
|
|
|
|
|
|
|
|
|
98.56% |
| ZIP TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| ZIP(Scrambled) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| β-N-methylamino-L-alanine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| βGlcCer |
|
|
|
|
|
|
|
|
|
|
|
|
| ζ-Stat |
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| ζ-Stat trisodium |
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| N-Desmethyltamoxifen hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Citronellyl acetate |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| (20R)-Ginsenoside Rh1 |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Tazanolast |
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| N-Desmethyltamoxifen |
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Forskolin |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Phorbol 12-myristate 13-acetate |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Bacopaside I |
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| Procyanidin A1 |
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| (-)-Indolactam V |
|
|
|
|
|
|
|
|
|
|
|
98.42% |
| Nefiracetam |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Cercosporamide |
|
|
|
|
|
|
|
|
|
|
|
|
| Cercosporin |
|
|
|
|
|
|
|
|
|
|
|
98.90% |
| Ingenol |
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Ingenol 3,20-dibenzoate |
|
|
|
|
|
|
|
|
|
|
|
99.16% |
| Ingenol Mebutate |
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| Enzastaurin |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Valrubicin |
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Staurosporine |
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| Myricitrin |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| (+)-Eudesmin |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| (±)-Myrtenol |
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Forskolin |
|
|
|
|
|
|
|
|
|
|
|
|
| Verbascoside |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Flosequinan |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Fasudil |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Phellopterin |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Daphnetin |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| (±)-1,2-Diolein |
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| (±)-1,2-Diolein-CC3 |
|
|
|
|
|
|
|
|
|
|
|
|
| (Rac)-Anemonin |
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| Chelerythrine-d6 chloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Chelerythrine |
|
|
|
|
|
|
|
|
|
|
|
|
| Enzastaurin dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Fasudil Hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Fasudil hydrochloride semihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
| Chelerythrine chloride |
|
|
|
|
|
|
|
|
|
|
|
99.11% |
| Mitoxantrone-d8 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Mitoxantrone dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| Phellodendrine chloride |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Ionomycin |
|
|
|
|
|
|
|
|
|
|
|
99.27% |
| Ionomycin calcium |
|
|
|
|
|
|
|
|
|
|
|
98.32% |
| Hypocrellin A |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Midostaurin |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Midostaurin-d5 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Leucosceptoside A |
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Mitoxantrone-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mitoxantrone |
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Decursin |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Decursin-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
| Decursinol angelate |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Cytidylate kinase |
|
|
|
|
|
|
|
|
|
|
|
|
| Bryostatin 1 |
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Bakkenolide A |
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Danazol |
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Hypericin |
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| Aurothiomalate disodium |
|
|
|
|
|
|
|
|
|
|
|
|
| Aurothiomalate sodium |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Psychosine-d5 |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Psychosine-d7 |
|
|
|
|
|
|
|
|
|
|
|
99% |
| Psychosine |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Gondoic acid |
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Ruboxistaurin |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Ruboxistaurin mesylate |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Ruboxistaurin hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Ruboxistaurin-d6 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Phellodendrine |
|
|
|
|
|
|
|
|
|
|
|
|